Onyx Bridge Wealth Group’s Akebia Therapeutics AKBA Stock Holding History

Onyx Bridge Wealth Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.9K	Hold	15,000	–	–	﹤0.01%	370
2025 Q4	$24.1K	Hold	15,000	–	–	﹤0.01%	363
2025 Q3	$41K	Hold	15,000	–	–	﹤0.01%	362
2025 Q2	$54.6K	Hold	15,000	–	–	0.01%	310
2025 Q1	$28.8K	Hold	15,000	–	–	﹤0.01%	289
2024 Q4	$28.5K	Hold	15,000	–	–	﹤0.01%	281
2024 Q3	$19.8K	Hold	15,000	–	–	﹤0.01%	282
2024 Q2	$15.3K	Hold	15,000	–	–	﹤0.01%	270
2024 Q1	$20.1K	Buy	15,000 +2,500	+20%	+$4K	﹤0.01%	259
2023 Q4	$15.5K	Hold	12,500	–	–	﹤0.01%	249
2023 Q3	$14.3K	Hold	12,500	–	–	﹤0.01%	234
2023 Q2	$11.4K	Hold	12,500	–	–	﹤0.01%	235
2023 Q1	$7K	Hold	12,500	–	–	﹤0.01%	185
2022 Q4	$8.03K	Hold	12,500	–	–	﹤0.01%	183
2022 Q3	$4K	Hold	12,500	–	–	﹤0.01%	171
2022 Q2	$5K	Buy	+12,500	New	+$5.25K	﹤0.01%	164

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Onyx Bridge Wealth Group's AKBA Position: Q1 2026 in Review

Onyx Bridge Wealth Group held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 15,000 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #370.

Onyx Bridge Wealth Group first reported a position in AKBA in Q2 2022 and has held it in 16 quarters since. The position peaked at $54.6K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Onyx Bridge Wealth Group held 15,000 shares of Akebia Therapeutics worth $20.9K as of Q1 2026.
Onyx Bridge Wealth Group left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Onyx Bridge Wealth Group's portfolio in Q1 2026, its #370 holding.
Onyx Bridge Wealth Group first reported a position in Akebia Therapeutics in Q2 2022 and has held it in 16 quarters since.
Onyx Bridge Wealth Group's Akebia Therapeutics position peaked at $54.6K in Q2 2025.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Onyx Bridge Wealth Group's 13F filing for Q1 2026, filed 22 Apr 2026.